As the pioneer in precision medicine and leading molecular science company, Caris Life Sciences® has one of the largest and most comprehensive databases of combined molecular and clinical outcomes data in the world. We’ve unleashed highly sophisticated AI bioinformatics and machine learning capabilities on our massive database, which is derived from Caris Molecular Intelligence® – the most comprehensive genomic profiling service available. We call it Caris MAI™ (molecular artificial intelligence), and it enables us to identify unique, proprietary signatures to classify cancer at the molecular level.
Using a cutting-edge artificial intelligence (AI) platform, we identified a molecular signature that is highly predictive of benefit from first-line chemotherapy with FOLFOX (in combination with bevacizumab) in patients with metastatic colorectal cancer. This signature was validated in 2 independent datasets, which included patients from the recently published TRIBE2 study. This signature, called FOLFOXai, is the first commercially available AI signature for the prediction of benefit from standard chemotherapy.
We have used machine learning to develop a highly accurate molecular disease classifier to assist with diagnosis based on DNA and RNA sequencing data. This predictor can be ordered by the oncologist to assist in any case where the diagnosis is uncertain.
com • pre • hen • sive
/ˌkämprəˈhensiv/ complete; including all or nearly all elements or aspects of something.
We define Comprehensive Genomic Profiling with:
The precision medicine era has arrived and molecular profiling has become standard of care for many cancer types, recommended by the NCCN Guidelines® and required for certain therapies (companion dx). More than ever, oncologists need a trusted profiling partner to provide reliable, high quality molecular information to guide more precise and individualized treatment decisions.
The Caris Molecular Intelligence® comprehensive tumor profiling approach to assess DNA, RNA and Proteins reveals the highest quality molecular blueprint to guide more precise and individualized treatment decisions that is proven to extend overall survival. More complete molecular insights and fewer missed opportunities from limited NGS testing panels or single tests.
Let’s connect so we can provide you the most comprehensive molecular intelligence for your patients.
or call 1.800.979.8669 (International:+41 21 533 53 00)